CA2882947A1 - Crystalline form of a reverse transcriptase inhibitor - Google Patents

Crystalline form of a reverse transcriptase inhibitor Download PDF

Info

Publication number
CA2882947A1
CA2882947A1 CA2882947A CA2882947A CA2882947A1 CA 2882947 A1 CA2882947 A1 CA 2882947A1 CA 2882947 A CA2882947 A CA 2882947A CA 2882947 A CA2882947 A CA 2882947A CA 2882947 A1 CA2882947 A1 CA 2882947A1
Authority
CA
Canada
Prior art keywords
compound
oxo
methyl
anhydrous form
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2882947A
Other languages
English (en)
French (fr)
Inventor
Courtney K. Maguire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2882947A1 publication Critical patent/CA2882947A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2882947A 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor Abandoned CA2882947A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
US61/705,780 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Publications (1)

Publication Number Publication Date
CA2882947A1 true CA2882947A1 (en) 2014-04-03

Family

ID=50388877

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2882947A Abandoned CA2882947A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Country Status (9)

Country Link
US (1) US9150539B2 (OSRAM)
EP (1) EP2900240B1 (OSRAM)
JP (2) JP6387349B2 (OSRAM)
CN (2) CN109384765A (OSRAM)
BR (1) BR112015005997A8 (OSRAM)
CA (1) CA2882947A1 (OSRAM)
ES (1) ES2773105T3 (OSRAM)
MX (1) MX362517B (OSRAM)
WO (1) WO2014052171A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598397B2 (en) 2013-12-04 2017-03-21 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309700B2 (en) * 2004-04-02 2007-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one
CN1993332B (zh) * 2004-07-27 2011-04-06 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物
JP5341881B2 (ja) * 2007-05-30 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー トリアゾロン類の製造方法
MX2010005483A (es) * 2007-11-20 2010-06-11 Merck Sharp & Dohme Inhibidores de transcriptasa inversa no nucleosidos.
HUE031785T2 (en) * 2010-03-30 2017-08-28 Merck Canada Inc Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor
EP2558093A4 (en) * 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR

Also Published As

Publication number Publication date
JP6387349B2 (ja) 2018-09-05
MX362517B (es) 2019-01-21
JP2015531372A (ja) 2015-11-02
WO2014052171A1 (en) 2014-04-03
BR112015005997A8 (pt) 2023-04-11
BR112015005997A2 (pt) 2017-07-04
CN109384765A (zh) 2019-02-26
EP2900240B1 (en) 2020-01-08
ES2773105T3 (es) 2020-07-09
CN104684557A (zh) 2015-06-03
EP2900240A1 (en) 2015-08-05
EP2900240A4 (en) 2016-07-13
US20150232447A1 (en) 2015-08-20
JP2018024683A (ja) 2018-02-15
US9150539B2 (en) 2015-10-06
MX2015003767A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
DK1910370T3 (en) PYRIDINQUINOLINE SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR
CN110678178B (zh) Mk2抑制剂的形式和组合物
ME01985B (me) Kalijumova so inhibitora hiv integraze
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
TW201617347A (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
WO2015103456A1 (en) Crystalline forms of afatinib di-maleate
NO324495B1 (no) Polymorf form av 5-klor-3-(4-metansulfonylfenyl)-6'-metyl-[2,3']bipyridinyl, farmasoytisk preparat inneholdende denne, og anvendelse av forbindelsen for fremstilling av et medikament
EP2900240B1 (en) Crystalline form of a reverse transcriptase inhibitor
WO2018109786A1 (en) Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
KR20130103483A (ko) Ｎ-［2-［［(2,3-디플루오로페닐)메틸］티오］-6-｛［(1ｒ,2ｓ)-2,3-디히드록시-1-메틸프로필］옥시｝-4-피리미디닐］-1-아제티딘술폰아미드의 신규 결정질 형태
EP2598147A1 (en) N-methylformamide solvate of dasatinib
WO2016172333A1 (en) A solid state form of perampanel
EP2575465A1 (en) Salts of raltegravir
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
WO2017032705A1 (en) Crystalline form of omarigliptin
WO2023134769A1 (zh) 4'-取代核苷的晶体、其制备方法、组合物和用途
CA2566803A1 (en) Drying process for preparing crystalline solid famciclovir
WO2011016044A1 (en) Novel polymorphs of adefovir dipivoxil
HK1219484B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
HK1227853B (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
KR20110044864A (ko) 4-(5-((1ｒ)-1-[5-(3-클로로페닐)이속사졸-3-일]에톡시)-4-메틸-4ｈ-1,2,4-트리아졸-3-일)피리딘의 신규 결정질 형태
CA2884248A1 (en) Novel polymorphs of azilsartan
CA2733922A1 (en) A crystalline form of 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180917

FZDE Discontinued

Effective date: 20220406

FZDE Discontinued

Effective date: 20220406

FZDE Discontinued

Effective date: 20220406

FZDE Discontinued

Effective date: 20220406